Summary
Only one of the fourteen claims is supported by the label; the rest are not supported.
Category Scores
Accurate Statements
Lacosamide is commonly used to treat partial-onset seizures.
Label indicates MOTPOLY XR is indicated for treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
Unsupported Statements
Lacosamide is an antiepileptic medication.
The label lists indication for partial-onset seizures but does not explicitly state lacosamide as an 'antiepileptic medication'.
Lacosamide is also used to treat neuropathic pain.
No label indication for neuropathic pain in the provided sections.
A study published in Epilepsia in 2013 found that lacosamide was not associated with an increased risk of major congenital malformations in pregnant women with epilepsy.
No specific study or pregnancy safety data are provided in the label sections.
The 2013 Epilepsia study noted that the sample size was small, and more research was needed to confirm these findings.
No study-specific commentary is present in the provided label sections.
The EMA reviewed lacosamide's safety during pregnancy in 2017 and found that lacosamide was not associated with an increased risk of birth defects, but the available data were limited.
No EMA pregnancy safety assessment details are present in the provided label sections.
The EMA recommended that lacosamide be used during pregnancy only when the benefits outweigh the risks.
No EMA labeling guidance for pregnancy risk-benefit threshold is present in the provided sections.
The US FDA classifies lacosamide as a category C medication, meaning that animal studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women.
No FDA pregnancy category information is provided in the supplied sections.
The data available on lacosamide safety during pregnancy are limited.
No explicit pregnancy safety data summary is provided in the provided sections.
DrugPatentWatch.com states that lacosamide's patent expires in 2028, which may lead to increased generic competition and potentially lower prices.
Patent and pricing information is not part of the provided FDA label sections.
The article notes that lacosamide safety during pregnancy is still a topic of debate.
No article discussion is present in the provided label sections.
Regular prenatal check-ups and ultrasounds can help identify potential issues early on while taking lacosamide.
No pregnancy management recommendations are provided in the provided sections.
If you're taking lacosamide and become pregnant, you should contact your healthcare provider immediately to discuss treatment options.
No such patient action guidance is present in the provided sections.
There are alternative medications available for treating epilepsy and nerve pain during pregnancy; a healthcare provider can help determine the best course of action.
No alternatives or pregnancy-related treatment guidance is present in the provided sections.
The FAQ states that lacosamide may be associated with an increased risk of birth defects, particularly if taken in high doses or for extended periods.
No FAQ content is present in the provided sections.
Contradictions
Important Omissions
Detailed pregnancy safety data (e.g., fetal risk category, trimester-specific guidance) is not summarized from 8.1 Pregnancy section.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Only label-supported indication is partial-onset seizures; no label-supported safety risk statements are provided in the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most pregnancy- and external-source claims are not supported by the provided label sections.
Suggested Improvement
Limit claims to label-supported indications (partial-onset seizures) and pregnancy sections; avoid citing EMA/US pregnancy category details or non-label sources without explicit labeling references.